Jacques Buxeraud (Professeur des universités) , Sébastien Faure (Professeur des universités)
{"title":"Le quizartinib (Vanflyta®), un nouvel antinéoplasique","authors":"Jacques Buxeraud (Professeur des universités) , Sébastien Faure (Professeur des universités)","doi":"10.1016/j.actpha.2025.05.005","DOIUrl":"10.1016/j.actpha.2025.05.005","url":null,"abstract":"<div><div>Le quizartinib est un nouvel antinéoplasique de la classe des inhibiteurs de protéines kinases, destiné à traiter les patients adultes atteints de leucémie aiguë myéloïde nouvellement diagnostiquée, avec mutation du gène <em>FLT3-ITD</em>.</div></div><div><div>Quizartinib is a new antineoplastic agent in the protein kinase inhibitor class, designed to treat adult patients with newly diagnosed acute myeloid leukemia with FLT3-ITD gene mutation.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 10-12"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chloé Bruneau (Pharmacien toxicologue) , Jérémy Lecot (Pharmacien toxicologue) , Morgane Cellier (Pharmacien toxicologue) , Jean-Charles Jouhanneau (Technicien de recherche et de formation) , Anne Landreau (Pharmacienne, professeure des Universités en mycologie et botanique) , Gaël Le Roux (Pharmacien toxicologue)
{"title":"Le syndrome phalloïdien","authors":"Chloé Bruneau (Pharmacien toxicologue) , Jérémy Lecot (Pharmacien toxicologue) , Morgane Cellier (Pharmacien toxicologue) , Jean-Charles Jouhanneau (Technicien de recherche et de formation) , Anne Landreau (Pharmacienne, professeure des Universités en mycologie et botanique) , Gaël Le Roux (Pharmacien toxicologue)","doi":"10.1016/j.actpha.2025.05.015","DOIUrl":"10.1016/j.actpha.2025.05.015","url":null,"abstract":"<div><div>Le syndrome phalloïdien est provoqué par l’ingestion de champignons appartenant à trois genres : <em>Amanita</em>, <em>Lepiota</em> et <em>Galerina</em>. Il comprend trois phases : une période de latence asymptomatique d’au moins six heures, une phase gastro-intestinale et une phase viscérale. Depuis l’amélioration de la réanimation symptomatique, la mortalité est désormais liée à l’insuffisance hépatocellulaire. Toute suspicion d’intoxication phalloïdienne doit faire l’objet d’une prise en charge hospitalière.</div></div><div><div>Phalloid syndrome is caused by ingestion of mushrooms belonging to three genera: Amanita, Lepiota and Galerina. It comprises three phases: an asymptomatic latency period of at least six hours, a gastrointestinal phase and a visceral phase. Since symptomatic resuscitation has improved, mortality is now linked to hepatocellular failure. Any suspicion of phalloid poisoning must be treated in hospital.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 50-54"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jérôme Sicard (Docteur en pharmacie) , Mohammed Lamdaoir (Docteur en pharmacie)
{"title":"Impulsion, un dispositif d’oncologie intégrative au cœur du territoire","authors":"Jérôme Sicard (Docteur en pharmacie) , Mohammed Lamdaoir (Docteur en pharmacie)","doi":"10.1016/j.actpha.2025.05.013","DOIUrl":"10.1016/j.actpha.2025.05.013","url":null,"abstract":"<div><div>Le dispositif Impulsion permet, pendant et après un cancer, à 200 personnes de bénéficier, à moindres frais et au plus près de leur lieu de vie, d’un suivi personnalisé en oncologie intégrative sélectionné parmi neuf soins. L’objectif est d’assurer à tous les patients un égal accès aux compétences locales en complément de la prise en soins proposée au sein des établissements de santé.</div></div><div><div>The Impulsion program enables 200 people, during and after cancer, to benefit from personalized, low-cost integrative oncology care selected from nine different treatments, as close as possible to where they live. The aim is to ensure that all patients have equal access to local expertise, as a complement to the care offered in healthcare establishments.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 40-45"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean-Michel Mrozovski (Président d’honneur de la Coopération pour la valorisation de l’acte officinal (CVAO))
{"title":"Dépistage et suivi des traitements de la DMLA","authors":"Jean-Michel Mrozovski (Président d’honneur de la Coopération pour la valorisation de l’acte officinal (CVAO))","doi":"10.1016/j.actpha.2025.05.017","DOIUrl":"10.1016/j.actpha.2025.05.017","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 59-61"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samuel Legeay (Maître de conférences des universités), Sébastien Faure (Professeur des universités)
{"title":"Un syndrome anticholinergique","authors":"Samuel Legeay (Maître de conférences des universités), Sébastien Faure (Professeur des universités)","doi":"10.1016/j.actpha.2025.05.007","DOIUrl":"10.1016/j.actpha.2025.05.007","url":null,"abstract":"<div><div>Une ordonnance complexe peut regrouper plusieurs médicaments à potentiel anticholinergique qui sont susceptibles de s’accumuler et de favoriser les syndromes gériatriques qui comprennent des troubles cognitifs et fonctionnels. Les charges anticholinergiques centrales et périphériques peuvent être calculées à l’aide d’échelles validées. L’analyse pharmaceutique de l’ordonnance permettra au pharmacien d’officine d’évaluer la charge anticholinergique du traitement et de proposer au médecin prescripteur des alternatives thérapeutiques afin de la diminuer et de limiter ses impacts cliniques.</div></div><div><div>A complex prescription may group together several drugs with anticholinergic potential, which are likely to accumulate and promote geriatric syndromes that include cognitive and functional impairment. Central and peripheral anticholinergic loads can be calculated using validated scales. Pharmaceutical analysis of the prescription will enable the dispensing pharmacist to assess the anticholinergic load of the treatment and suggest therapeutic alternatives to the prescribing physician in order to reduce it and limit its clinical impact.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 15-17"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Les immunothérapies, bénéfices et risques","authors":"Eurydice Angeli (Oncologue médical, PHD)","doi":"10.1016/j.actpha.2025.05.010","DOIUrl":"10.1016/j.actpha.2025.05.010","url":null,"abstract":"<div><div>L’immunothérapie est une véritable révolution thérapeutique, largement prescrite aujourd’hui en oncologie. Cependant, il est important de rapidement identifier les effets indésirables auto-immuns qu’elle est susceptible d’engendrer.</div></div><div><div>Immunotherapy is a genuine therapeutic revolution, widely prescribed in oncology today. However, it is important to quickly identify the autoimmune side effects it can cause.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 648","pages":"Pages 22-26"},"PeriodicalIF":0.1,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144702570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
